VANCOUVER, Sept. 5 Ondine-Trial-Results
VANCOUVER, Sept. 5 /PRNewswire-FirstCall/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that a poster entitled "Photodisinfection in the Treatment of Chronic Periodontitis" will be presented by Company representatives at the American Academy of Periodontology's (AAP) annual meeting. This year's AAP meeting is being held at the Washington State Convention and Trade Center in Seattle, Washington on September 6-9, 2008.
"We are pleased to have the opportunity to present photodisinfection to the U.S. periodontal community," said Carolyn Cross, Ondine's President and CEO. "This peer-reviewed poster highlights the positive results of the Company's Multi-Centre Trial using its Photodisinfection System. Periodontal pockets treated with photodisinfection (220mW laser plus photosensitizer) in addition to scaling and root planing (SRP) yielded statistically significant reductions in pocket depth (p=0.01) as well as increases in clinical attachment level (p=0.002) when compared to pockets treated only with SRP."
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.
Forward-Looking Statements:
Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
SOURCE Ondine Biopharma Corporation
